The Other News

Tuesday
Nov 30th 2021
Text size
  • Increase font size
  • Default font size
  • Decrease font size
Home Lifestyle Wellness Local diarrhoea vaccine could save thousands

Local diarrhoea vaccine could save thousands

E-mail Print PDF

Press conference to annouce the rotavirus vaccineRotavirus vaccine developed in India demonstrates strong safety and efficacy.

 

New Delhi. The Government of India’s Department of Biotechnology (DBT) and Bharat Biotech has announced positive results from a Phase III clinical trial of a rotavirus vaccine developed and manufactured in India. Data from the trial, presented at the International Symposium on Rotavirus Vaccines for India—The Evidence and the Promise, showed ROTAVAC to have an excellent safety and efficacy profile.

The clinical study demonstrates for the first time that the India-developed rotavirus vaccine ROTAVAC is efficacious in preventing severe rotavirus diarrhoea in low-resource settings in India. ROTAVAC significantly reduced severe rotavirus diarrhoea by more than half- 56 per cent- during the first year of life, with protection continuing into the second year of life. Moreover, the vaccine also showed impact against severe diarrhoea of any cause.

"This is an important scientific breakthrough against rotavirus infections, the most severe and lethal cause of childhood diarrhoea, responsible for approximately 100,000 deaths of small children in India each year," said DBT Secretary Dr. K. Vijay Raghavan. "The clinical results indicate that the vaccine, if licensed, could save the lives of thousands of children each year in India."

The vaccine was developed through a unique social innovation partnership that brought together the experience and expertise of Indian and international researchers as well as the public and private sectors. The vaccine originated from an attenuated (weakened) strain of rotavirus that was isolated from an Indian child at the All India Institute of Medical Sciences in New Delhi in 1985-86.

The vaccine development partnership was supported by DBT, the Bill & Melinda Gates Foundation, the Research Council of Norway, and the UK Department for International Development. Bharat Biotech invested important technical, manufacturing, and financial resources towards vaccine development. ROTAVAC is an oral vaccine and is administered to infants in a three-dose course at the ages of 6, 10, and 14 weeks. It is given alongside routine immunisations in the UIP vaccines recommended at these ages.

 

India Facts

A little over 2000 meters above sea level, the cricket ground in Chail, Himachal Pradesh, is the highest in the world.

Hot Topic

 

Made In India at London Fashion Week

  FAD International Academy unveils House of MEA promoting Indian designers at Fashion ...

 

Mobile phones to tackle malnutrition

 

Free BPO training for the youth

...

 

Cloud computing to create over 2 million jobs in India

A new research by IDC predicts 15 per cent of total jobs created by cloud across the worl...

 

ग्रामीण बच्चों ने जीते कम्प्यूटर और साईकिल

सोनीपत के एक गाँव में प्रतिभावान व...

Our Partners

Banner

Advertisements